Evidence map›Paper›PMID 20155608›Full record

Trial reportJournal of addictive diseases2009

A trial to reduce hepatitis C seroincidence in drug users.

Michael D Stein, Debra S Herman, Bradley J Anderson

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of addictive diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael D SteinGeneral Research Medicine, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA. Michael_Stein@brown.edu
Debra S Herman
Bradley J Anderson

Funding

A TRIAL TO REDUCE HEPATITIS C AMONG INJECTION DRUG USERSR01DA013759 · NIDA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI STEIN, MICHAEL D · 2000 to 2003
$1.9M
MIDCAREER INVESTIGATOR AWARD IN SUBSTANCE ABUSE RESEARCHK24DA000512 · NIDA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI STEIN, MICHAEL D · 2001 to 2010
$982k
DISCOVERY OF NOVEL MOLECULAR TARGETS FOR ENDOGENOUS AND SYNTHETIC CANNABINOIDSZ01DA000512 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHIPPENBERG, TONI · 2007 to 2008
$189k
Intramural NIH HHS Z01 DA000512NIDA NIH HHS DA13759NIDA NIH HHS K24 DA000512NIDA NIH HHS R01 DA013759
6 · The paper itself

Abstract

To test whether a four-session motivational intervention would reduce hepatitis C virus (HCV) seroincidence among injection and non-injection drug users compared to an assessment-only condition, we performed a randomized 24-month clinical trial. At baseline, 277 participants reported using heroin or cocaine at least three times weekly were HCV antibody negative, 65% were male and 46% were Caucasian and 39% reported having injected drugs. Of the 15 (5.4%) individuals who seroconverted, all reported injecting drugs either at baseline or during follow-up. Seroconversion rates did not differ significantly by treatment assignment (p =.79). The annual HCV incident rate was 8.20 (95% confidence interval [CI] = 4.76-14.13) for injectors and 0.74 (95% CI = 0.19-2.98) for non-injectors per 100 person-years. Significantly fewer participants in the intervention group initiated injection drug use behaviors (p =.009). This intervention was no more effective at reducing HCV seroconversion than assessment alone but did decrease injection initiation.

Indexed as

AdultCounselingFemaleGoalsHealth PromotionHepatitis CHepatitis C AntibodiesHumansIncidenceMaleMiddle AgedRhode IslandRisk-TakingSecondary PreventionSubstance Abuse, IntravenousSubstance-Related DisordersHepatitis C Antibodies

Identifiers

PMID20155608
PMCPMC2822987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.